This review identifies immune checkpoint inhibitors’ role in improving clinical outcomes for triple-negative breast cancer, highlighting combinatorial approaches.
Key Points
Improving clinical outcomes involves integrating immune modulation with targeted therapies for triple-negative breast cancer.
Recent advances have revealed distinct subtypes and vulnerabilities in triple-negative breast cancer, like BRCA1/2 mutations.
Targeting DNA repair pathways and using immune checkpoint inhibitors shows promise against this aggressive cancer subtype.
Successful strategies will need to tackle the significant resistance observed in treatments for triple-negative breast cancer.